Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis

Published:2018-01 Issue:1 Volume:5 Page:1536097
ISSN:2001-8525
Container-title:European Clinical Respiratory Journal
language:en
Short-container-title:European Clinical Respiratory Journal

Author:

Henriksen Daniel P.¹^ORCID,Bodtger Uffe²^ORCID,Sidenius Kirsten³,Maltbaek Niels⁴,Pedersen Lars⁵,Madsen Hanne⁶,Andersson Ehm A.⁷,Norgaard Ole⁷^ORCID,Madsen Louise Klokker⁷^ORCID,Chawes Bo L.⁸^ORCID

Affiliation:

1. Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark

2. Department of Respiratory Medicine, Næstved Hospital, Næstved, Denmark

3. Allergi og Lungeklinikken Helsingør, Helsingør, Denmark

4. Department of Medicine, Zealand University Hospital, Roskilde, Denmark

5. Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark

6. Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark

7. The Danish Medicines Council Secretariat, Copenhagen, Denmark

8. COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark

Funder

no funding

Publisher